Table 1 Baseline characteristics in the first-line switch-maintenance and second-line subgroups
Characteristics | 1 L-mn subgroup (n = 90) | 2 L subgroup (n = 60) |
|---|---|---|
Median age (IQR), years | 59 (52.0–67.0) | 62.5 (51.5–66.0) |
Sex, n (%) | ||
Male | 68 (75.6) | 46 (76.7) |
Female | 22 (24.4) | 14 (23.3) |
ECOG PS, n (%) | ||
0 | 37 (41.1) | 23 (38.3) |
1 | 53 (58.9) | 37 (61.7) |
Geographic region, n (%) | ||
North America | 31 (34.4) | 32 (53.3) |
Asia | 34 (37.8) | 10 (16.7) |
Europe | 25 (27.8) | 18 (30.0) |
Race, n (%) | ||
White | 44 (48.9) | 36 (60.0) |
Asian | 35 (38.9) | 13 (21.7) |
Black | 4 (4.4) | 4 (6.7) |
Other | 7 (7.8) | 7 (11.7) |
Histology, n (%) | ||
Tubular | 18 (20.0) | 3 (5.0) |
Signet ring | 17 (18.9) | 13 (21.7) |
Mucinous | 4 (4.4) | 4 (6.7) |
Papillary | 1 (1.1) | 0 |
Other/not specified | 1 (1.1) | 0 |
Unknown | 37 (41.1) | 39 (65.0) |
PD-L1 expression status based on ≥1% cutoff on tumor cells, n (%) | ||
PD-L1+ | 26 (28.9) | 20 (33.3) |
PD-L1− | 51 (56.7) | 25 (41.7) |
Not evaluable | 13 (14.4) | 15 (25.0) |
HER2 status, n (%) | ||
HER2− | 62 (68.9) | 29 (48.3) |
HER2+ | 4 (4.4) | 5 (8.3) |
Unknown | 24 (26.7) | 26 (43.3) |
Microsatellite status, n (%) | ||
Low | 1 (1.1) | 0 |
Stable | 21 (23.3) | 17 (28.3) |
High | 2 (2.2) | 2 (3.3) |
Unknown | 66 (73.3) | 41 (68.3) |
Prior gastrectomy, n (%) | 24 (26.7) | 14 (23.3) |
Metastatic disease status at study entry, n (%) | ||
M0 | 5 (5.6) | 2 (3.3) |
M1 | 85 (94.4) | 58 (96.7) |
Tumor size at baselinea | ||
Median (IQR), mm | 33 (19–52) | 44 (25–69.5) |
Unknown, n (%) | 1 (1.1) | 1 (1.7) |
Best response to prior anticancer therapy, n (%) | ||
Complete response | 0 | 1 (1.7) |
Partial response | 25 (27.8) | 8 (13.3) |
Stable disease | 59 (65.6) | 23 (38.3) |
Progressive disease | 0 | 22 (36.7) |
Not evaluable or unknown | 6 (6.7) | 5 (8.3) |
Prior anticancer therapy (any setting), n (%) | 90 (100) | 60 (100) |
Number of prior lines of anticancer therapy for metastatic or locally advanced disease, n (%) | ||
0 | 1 (1.1) | 5 (8.3) |
1 | 87 (96.7) | 53 (88.3) |
2 | 2 (2.2) | 1 (1.7) |
Unknown | 0 | 1 (1.7) |
Median prior lines (range) | 1.0 (0–2) | 1.0 (0–2) |
Interval from end of prior chemotherapy to start of avelumab therapy | ||
Median (IQR), days | 45 (35–64) | 77 (49–135) |
Data missing, n (%) | 8 (8.9) | 15 (25.0) |